ImProDia

Immune System Diagnostic Blood Test

Health Tech & Life Sciences
Active
Seed Herzliya, Israel Founded 2012
Last updated 2026-06-18
Total raised
$200K
Last: 2014-10
Stage
Seed
Founded
2012
Headcount
1
HQ
Herzliya, Israel
Sector
Health Tech & Life Sciences

About

Improdia is a diagnostic company that develops clusters of novel proprietary biomarkers for monitoring the immunity status of patients suffering from diseases associated with chronic inflammation. The technology enables the tracking of disease regression, recurrence and treatment response, and immunity status. The technology will help to identify patients who are most likely to benefit from a particular therapeutic treatment and to predict the occurrence of complications before they are evident. Improdia's technology has potential as a prognostic/diagnostic kit for a wide range of chronic inflammatory diseases and as a key tool for pharmaceutical companies in the development of new drugs for cancer, Alzheimer's disease, heart disease, rheumatology, and pulmonary diseases. Improdia's R&D focuses on developing a clinical prototype that can be successfully used in multi-center trials. The emphasis of the work revolves around product establishment and characterization, process standardization, and quality control validation. Improdia was established based on a project conceived in the Department of Immunology under Professor Michal Baniyash at the Hebrew University of Jerusalem.

Funding history · 2 rounds · $200K total

2014-10
Undisclosed
2012-06
Grant $200K

Q&A

What is ImProDia's primary focus?
ImProDia is a diagnostic company that develops novel proprietary biomarkers for monitoring the immunity status of patients with chronic inflammatory diseases. The technology aims to track disease regression, recurrence, and treatment response.
When was ImProDia founded?
ImProDia was founded in January 2012.
How much funding has ImProDia raised in total?
ImProDia has raised a total of $200,000.
What was ImProDia's most recent funding round?
ImProDia's most recent funding round occurred in October 2014, with participation from Citrine S A L.
What is the current product stage of ImProDia's technology?
ImProDia's technology is currently in the clinical trial stage.
Who are the co-founders of ImProDia?
The co-founders of ImProDia are Tuvia Sofinzon and Raphael Nir. Tuvia Sofinzon is no longer with the company.
What is ImProDia's primary sector?
ImProDia's primary sector is Health Tech & Life Sciences.

Team · 2

Founder · Founder (No longer with the company)
LinkedIn ↗
Founder · Co-Founder
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyTest Diagnostics & Screening
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticalsHealthcareLaboratories
Business model
B2B

Highlights

1 PatentsVerified

Tags

cancermedical-technologiesoncologybiomarkersimmunologyblood-testdiagnosticsbiotechnologyinflammatory-diseaseslaboratoriesnon-invasivepersonalized-medicineautoimmune-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websiteimprodia.co.il
LinkedInlinkedin.com/company/13990246

Identifiers & details

Founded2012-1
Employees (exact)1

Radar intelligence

Publications (Crossref)

Works3

Web history (Wayback)

Domainimprodia.co.il

Certificate / subdomain footprint

Subdomains6